title: Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer.
abstract: The objective of this multicenter phase II study was to evaluate the activity of docetaxel in previously untreated small cell lung cancer. Fourteen patients were treated at a dose of 75 mg/m2 intravenously every three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3%. Toxicity was mild. We conclude that docetaxel has, at the dose given in this study, little activity in previously untreated small cell lung cancer.
authors.affiliation: Hôtel-Dieu de Montréal, Qué., Canada.
authors.forename: J
authors.initials: J
authors.lastname: Latreille
authors.forename: Y
authors.initials: Y
authors.lastname: Cormier
authors.forename: H
authors.initials: H
authors.lastname: Martins
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: B
authors.initials: B
authors.lastname: Fisher
authors.forename: E A
authors.initials: EA
authors.lastname: Eisenhauer
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel